Swedish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
Sida 1 från 175 resultat
Treatment-related dysgeusia in head and neck cancer patients.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Head and neck cancer patients treated with radiotherapy and/or chemotherapy agents may develop altered taste acuity. This, together with radiation induced xerostomia and dysphagia, is a major contributory factor to the anorexia and concomitant morbidity often seen in this group of patients. This
[Taste dysfunction (dysgeusia) and radioiodine therapy of thyroid cancer - Be aware of side effects by antidepressants and sedatives].
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
In addition to xerostomia, taste dysfunction (hypo-, dysgeusia) is an independent side effect of radioiodine therapy of thyroid cancer. Hypogeusia results from damage of the small mucous salivary glands in the vicinity of the taste buds. Particularly in those patients, who are treated with drugs
[Taste dysfunction (dysgeusia) and radioiodine therapy of thyroid cancer - be aware of side effects by antidepressants and sedatives. Vorschädigung durch Antidepressiva und Sedativa beachten].
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
In addition to xerostomia, taste dysfunction (hypo-, dysgeusia) is an independent side effect of radioiodine therapy of thyroid cancer. Hypogeusia results from damage of the small mucous salivary glands in the vicinity of the taste buds. Particularly in those patients, who are treated with drugs
Baseline Dysgeusia in Chemotherapy-Naïve Non-Small Cell Lung Cancer Patients: Association with Nutrition and Quality of Life.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Purpose: Dysgeusia can be found in 50% of cancer patients undergoing chemotherapy. Nonetheless, dysgeusia can be present in treatment-naïve patients, and may negatively impact nutrition and quality of life. Methods: Treatment-naïve non-small cell lung cancer (NSCLC) was assessed for
Successful treatment of crizotinib-induced dysgeusia by switching to alectinib in ALK-positive non-small cell lung cancer.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
We describe a case of dysgeusia that developed gradually over one week after initiation of crizotinib administration for treatment of ALK-positive non-small cell lung cancer, necessitating discontinuation of the agent. The symptom was accompanied by progressive loss in appetite and body weight.
Dysgeusia in symptomatic syndrome of inappropriate antidiuretic hormone secretion: think of lung cancer.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
The case of a 60-year-old woman who presented with marked dysgeusia to all food and symptomatic syndrome of inappropriate antidiuretic hormone secretion (SIADH) is described. She eventually turned out to have metastatic small cell lung cancer. The case study explores the interesting constellation of
Acupuncture Therapy in Post-Radiation Head-and-Neck Cancer with Dysgeusia
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Background: Radiation therapy for head-and-neck cancer can cause side-effects, including pain, nausea, vomiting, sensory disorders such as anosmia and dysgeusia, dysphagia, xerostomia, hot flashes, fatigue, sleep disorders, and even anxiety and depression disorders. Therapies using
Photobiomodulation Therapy in the Treatment of Oral Mucositis, Dysgeusia and Oral Dryness as Side-Effects of Head and Neck Radiotherapy in a Cancer Patient: A Case Report.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Successful management of oral mucositis, dysgeusia and oral dryness was made with fivesessions of photobiomodulation. The severity of oral mucositis was measured according to the World Health Organization scale for the assessment of oral mucositis. Dysgeusia testing was performed according to the
A systematic review of dysgeusia induced by cancer therapies.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
OBJECTIVE
The purpose was to review relevant scientific papers written since 1989 which focused on the prevalence and management of dysgeusia as an oral side effect of cancer treatment.
METHODS
Our literature search was limited to English language papers published between 1990 and 2008. A total of
Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND
We hypothesized that the adverse event (AE) profile of cabazitaxel with regard to alopecia, nail changes, neuropathy, and dysgeusia differs from docetaxel.
METHODS
Prospectively collected data on treatment-emergent AEs (frequency and grade [G]) from clinical trial databases of docetaxel
Temporal lobe tumor manifested by localized dysgeusia.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Undiagnosed lung cancer presenting with dysgeusia.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Drug-related Dysgeusia: A Systematic Review.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
Integrin receptor imaging of breast cancer: a proof-of-concept study to evaluate 99mTc-NC100692.
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
The present study was a proof-of-concept study to provide an initial indication of the efficacy and safety of imaging malignant breast tumors using (99m)Tc-NC100692. The agent is a small peptide with high affinity for integrin receptors that are upregulated and expressed preferentially on
Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
The poly(ADP-ribose) polymerase inhibitor rucaparib is approved as monotherapy in the treatment and maintenance settings for women with relapsed ovarian cancer in the European Union and the United States. We review the safety profile of rucaparib in both settings and provide recommendations for the
Den mest kompletta databasen med medicinska örter som stöds av vetenskapen
- Fungerar på 55 språk
- Växtbaserade botemedel som stöds av vetenskap
- Örter igenkänning av bild
- Interaktiv GPS-karta - märka örter på plats (kommer snart)
- Läs vetenskapliga publikationer relaterade till din sökning
- Sök efter medicinska örter efter deras effekter
- Organisera dina intressen och håll dig uppdaterad med nyheterna, kliniska prövningar och patent
Skriv ett symptom eller en sjukdom och läs om örter som kan hjälpa, skriv en ört och se sjukdomar och symtom den används mot.
* All information baseras på publicerad vetenskaplig forskning
